Dyadic International (DYAI) Stock Price
Dyadic International Price
Revenue at Dyadic International has contracted by 12.4% per year over the past 19 years to 1.23 M USD. Earnings per share have grown at 51.5% per year over the last 6 years. Dyadic International's net margin stands at -597.6%, down from -543.7% several years earlier.
Dyadic International stock price
Dyadic International business model & stock analysis
Frequently asked questions about Dyadic International
The main competitors of Dyadic International Inc in the market are companies such as Novozymes A/S, Codexis Inc, and Danisco A/S.
Dyadic International Inc. is a biotechnology company that operates under a unique business model. The company primarily focuses on developing and commercializing innovative enzyme technologies. These enzymes are utilized in various industries such as animal health, biofuels, food and beverages, and industrial applications. With a strong emphasis on research and development, Dyadic International Inc. aims to create sustainable and cost-effective solutions for its customers. By harnessing the power of its proprietary C1 gene expression platform, the company strives to deliver high-performing enzymes that offer numerous benefits in terms of efficiency, environmental sustainability, and overall performance.
Dyadic International Inc is primarily active in the biotechnology industry.
Dyadic International Inc is a biotechnology company founded in 1979 in Jupiter, Florida. The company specializes in developing and producing enzymes and other proteins for various industries, including pharmaceuticals, animal health, and biofuels. With four decades of experience, Dyadic has built a strong reputation for its proprietary C1 gene expression platform, which enables efficient production of biologics at a lower cost. The company has established partnerships with leading organizations worldwide to further advance its technology and product portfolio. Dyadic International Inc continues to strive for innovation and contribute to the biotechnology industry through its cutting-edge research and development efforts.
Dyadic International Inc has achieved several significant milestones. The company successfully developed its proprietary C1 gene expression platform, which is highly efficient in producing biologic vaccines, therapeutic proteins, and other biopharmaceutical products. Dyadic has formed strategic partnerships with leading global companies to utilize the C1 technology in the production of vaccines for COVID-19, potentially addressing the global supply shortage. Additionally, the company has received numerous accolades and recognition for its innovative approach and contributions to the biotechnology industry. Dyadic International Inc continues to make advancements in the field, positioning itself as a key player in the biopharmaceutical sector.
Dyadic International Inc is primarily present in the United States and Europe.
Dyadic International Inc represents a set of core values and corporate philosophy that drive its operations. With a focus on innovation and technological advancements, Dyadic aims to deliver cutting-edge solutions in the field of biotechnology. The company's core values include integrity, collaboration, and a commitment to excellence. By fostering an inclusive and diverse environment, Dyadic emphasizes teamwork and cooperation to achieve its goals. Dyadic International Inc strives to create value for its stakeholders by leveraging its proprietary C1 gene expression system and continuing to advance the biopharmaceutical industry through continuous research and development efforts.
7 analysts currently rate the Dyadic International stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Dyadic International to generate revenue of 6.59 M USD and earnings per share of -0.13 USD.
Converted at the current exchange rate, the Dyadic International share trades at 0.41 EUR (0.46 USD).
The Dyadic International share (DYAI) is listed on 1 stock exchanges, including: NASDAQ (DYAI).
Dyadic International Inc is a company specializing in the development and manufacturing of biotechnological products. The company's business model is based on the use of proprietary technologies and collaboration with partners and customers. The company has three main business areas: 1. Biopharmaceuticals Dyadic has developed a proven platform for the production of proteins and antibodies that can be used in many medical applications. The company is working with various partners on the development of new therapies for diseases such as cancer, autoimmune diseases, and metabolic disorders. 2. Enzymes and cellulose The company also produces enzymes and cellulose-rich products used in the food and paper industries. For example, enzymes are used in the production of foods such as beer, cheese, and bread. The company is also working on finding new applications for the use of cellulose in healthcare and medical products. 3. Research and development Dyadic is also engaged in research and development of new technologies in biotechnology. The company is working on the development of DNA technologies and enzymes that can be applied in various industries. Dyadic also operates a combination of direct sales and partnerships. The company does not have its own marketing or sales department, but works with partners to sell its products and technologies. Dyadic is also interested in forming partnerships with other companies and academic research institutions to develop new technologies and products. Summary Dyadic International Inc is a biotechnology company specializing in the development and manufacturing of biopharmaceutical products, enzymes, and cellulose-containing products. The company has proprietary technologies that can be used in many applications and collaborates with partners and customers to develop new products and technologies. The company's focus is on researching and developing new technologies and applications.
The expected revenue of Dyadic International is 6.59 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Dyadic International is -4.10 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Dyadic International is currently -3.66. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Dyadic International stock.
The price-to-sales ratio (P/S) of Dyadic International is currently 2.28. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Dyadic International stock.
The Eulerpool Quality Score for Dyadic International is 3/10.
The ISIN of Dyadic International is US26745T1016. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Dyadic International is A0JK0A. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Dyadic International is DYAI. The ticker symbol is used to trade Dyadic International shares on the stock exchange.
Dyadic International stock
Dyadic International Peer Group
Dyadic International Ticker
Dyadic International FIGI
All fundamentals and in-depth analysis of Dyadic International
Our stock analysis for Dyadic International stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Dyadic International. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.